Spruce Biosciences keeps December BLA target for Sanfilippo therapy, spins off CRHX-101
Spruce reported third quarter 2026 results, reaffirmed a December BLA submission for TA-ERT, amended its Avenue loan, and separated CRHX-101 into a new subsidiary, Adrenyx Biosciences.
SEC filing